Researchers designed polymers that degrade MYC and KRAS by recruiting cellular machinery, slowing tumors and countering drug ...

Grove Biopharma, a private biotechnology company engineering protein-like polymers (PLPs) -- a new class of multifunctional biologics designed to address the most challenging intracellular drug ...

HYDRACs are a class of proteomimetic polymers designed to mark harmful proteins, like MYC and KRAS, for destruction rather than merely block their activity.

Please provide your email address to receive an email when new articles are posted on . Inhibiting RMB42 disrupted production of Myc proteins in pancreatic cancer cells. This approach could curtail ...

The growth protein, MYC, was consistently found with RBM42, which spurs MYC production, in human pancreatic tumors. Above, microscopy for MYC (red) and RBM42 (green) in a representative pancreatic ...

The findings were published in the journal Cell. The research was led by Leonie Uhl, Amel Aziba, and Sinah Löbbert, working with colleagues from the University of Würzburg (JMU), Massachusetts ...

Professor Heide Ford, the University of Colorado Medicine Endowed Chair in Pharmacology, gave a presentation Wednesday on her lab’s research into the role of proteins in cancer growth and spread at ...

Preventing the cell’s protein factories from making the notorious cancer-causing protein MYC could stop out-of-control tumors. For decades, scientists have tried to stop cancer by disabling the ...

For decades, scientists have tried to stop cancer by disabling the mutated proteins that are found in tumors. But many cancers manage to overcome this and continue growing. Now, scientists think they ...